Keeping Track: US FDA Receives Advanced Biologic BLAs From ImmunityBio, CSL; Nymox, Medac Stumble

The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

Two breakthrough therapy-designated novel biologics provided highlight among recent applications for US FDA approval. ImmunityBio’s interleukin-15 superagonist candidate aims to provide a secondary boost to augment the immunological response elicited by Bacillus Calmette-Guerin therapy for bladder cancer, while CSL Limited and uniQure N.V. plan to bring gene therapy to the treatment of hemophilia B.

AbbVie Inc. returned to Parkinson’s disease mainstay treatment carbidopa/levodopa with a prodrug formulation, ABBV-951, designed to be the first...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers